A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- End-stage Renal Disease
- Sponsor
- Humacyte, Inc.
- Enrollment
- 20
- Locations
- 3
- Primary Endpoint
- HAVG graft interventions
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG.
The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
Detailed Description
The HAVG is a sterile, non-pyrogenic, acellular tubular graft composed of human collagens and other natural extra-cellular matrix proteins. Upon implantation, it is anticipated (based on pre-clinical studies) that the collagen-based matrix comprising the graft will be infiltrated with host cells and re-modeled by the host. This will result in a vascular structure more similar to the histological composition of the native vascular tissue that may improve graft longevity and be less likely to become infected.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with ESRD who are not, or who are no longer candidates for creation of an autologous AV fistula and therefore need placement of an AV graft in the upper extremity to start or maintain hemodialysis therapy
- •Age 18 to 80 years old, inclusive
- •Suitable anatomy for implantation of straight forearm grafts or curved upper arm grafts (arterial anastomosis to radial or brachial artery, venous anastomosis to either brachial cephalic or very central basilica vein)
- •Hemoglobin ≥8 g/dL and platelet count ≥100,000 cells/mm3 prior to Day 1
- •Other hematological and biochemical parameters within a range consistent with ESRD and acceptable for the administration of general anesthesia prior to Day 1
- •Adequate liver function, defined as serum bilirubin ≤1.5 mg/dL; GGT, AST, ALT, and alkaline phosphatase ≤2x upper limit of normal or international normalized ratio (INR) ≤1.5 prior to Day
- •Able to communicate meaningfully with investigative staff, competent to give written informed consent, and able to comply with entire study procedures
- •Able and willing to give informed consent
- •Life expectancy of at least 1 year
Exclusion Criteria
- •History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within 6 months of study entry (Day 1), ventricular tachyarrhythmias requiring continuing treatment, or unstable angina
- •Uncontrolled or poorly controlled diabetes; hospitalization for poor glucose control within the previous 6 months is an absolute exclusion criterion
- •History or evidence of severe peripheral vascular disease in the upper limbs
- •Known or suspected central vein obstruction on the side of planned graft implantation
- •Stroke within 6 months of study entry (Day 1)
- •Candidate for renal transplantation
- •Treatment with any investigational drug or device within 60 days prior to study entry (Day 1)
- •Treatment with vitamin K-antagonists, factor Xa inhibitors, or direct thrombin inhibitors within the month prior to study entry (Day 1)
- •Female patients who are pregnant, intending to become pregnant, nursing or intending to nurse during the study
- •Female patients of child bearing potential (not surgically sterile or at least 2 years post menopause) who do not use a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly), eg, implants, injectables, combined oral contraceptives in combination with a barrier method, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
Outcomes
Primary Outcomes
HAVG graft interventions
Time Frame: From baseline to week 26 after HAVG implantation.
Graft interventions of each patient will be documented.
Adverse Events
Time Frame: From baseline to week 26 after HAVG implantation.
Frequency and severity of AEs of each patient will be documented.
HAVG graft assessment
Time Frame: From baseline to week 26 after HAVG implantation.
The incidence of aneurysm formation, anastomotic bleeding or rupture, graft infection and irritation/inflammation/infection at the implantation site will be assessed by Doppler ultrasound and tabulated.
HAVG patency rate
Time Frame: at Week 26 after HAVG implantation
Determine the patency (primary, primary assisted and secondary) rate of the Humacyte HAVG by Doppler ultrasound.
Secondary Outcomes
- Change from baseline in Panel Reactive Antibody(From baseline to day 29, weeks 12 and 26 after HAVG implantation.)
- Development of IgG antibodies(From baseline to day 29, weeks 12 and 26 after HAVG implantation.)
- Graft interventions(At each visit, i.e. day 1, day 4-7, day 15, day 29, day 57, week 12, week 16, 20, 26 after HAVG implantation.)
- HAVG patency rates(at 12, 18, 24 months after HAVG implantation.)